QT Imaging heads into its third-quarter report with a straightforward problem: the company has spent three straight calls reaffirming roughly $39 million in 2026 revenue, and the first half of the year delivered about $14 million of it. That leaves around $25 million to book in the final two quarters, a pace nearly 80% above what the business generated from January through June. The report due after the close on November 10 is the first real checkpoint on whether that back-end loaded plan is on track or whether the unchanged target is starting to look stale.
The Street has largely bought management's number, with full-year revenue consensus sitting at about $38.7 million, a hair below the company's outlook rather than above it. No meaningful quarterly per-share estimate is available, which is fitting for a small, loss-making device maker where the story is unit shipments and revenue conversion rather than earnings. Last quarter's loss of $0.19 per share was distorted by an $8.3 million non-cash charge tied to modifying the Linrock Lake loan, so the cleaner gauge will be the operating loss, which widened to $1.9 million in the second quarter from $1.0 million a year earlier.
The arithmetic is what makes this quarter interesting. Second-quarter revenue of $7.4 million came on 15 scanners, roughly $490,000 per unit, and management pointed to 15 shipments in the third quarter and 17 in the fourth. At recent per-unit revenue, those volumes would fall well short of what the full-year target requires. Closing the gap would take some combination of more units, richer pricing or mix, or additional revenue beyond scanner sales, and the call acknowledged that hitting the goal leans on distributor-contracted volumes. A third quarter that merely matches the second would technically meet the shipment outlook while making the annual number harder to defend. A clear step up in revenue, or a credible bridge to the fourth quarter, would validate the guidance.
The operating details matter too. Gross margin was 41% in each of the first two quarters, down from 50% a year ago as the benefit of cheaper legacy inventory faded. Stability there would be acceptable; further slippage would raise questions about pricing in international markets. Management also conceded that end-customer utilization has been slower than hoped, requiring direct sales support, and that conflict in the Gulf continues to delay Middle East activity. Progress on newly won approvals in Saudi Arabia and Israel, the Pakistan agent partnership, the expanded U.S. direct sales team and the start of the planned Mayo study comparing QT scans with MRI would all help show the commercial foundation is broadening. Cash, which stood near $14.2 million in early August after a $10 million offering, is worth tracking given the higher 12% loan rate.
The market has not waited patiently. Shares have fallen about 29% since the last report, trailing the S&P 500 by roughly 26 points, and at $2.15 they sit essentially at the bottom of the post-earnings range and about half their 200-day moving average of $4.25. Bullish sentiment has collapsed to 34.1% from 93.5% heading into last quarter, suggesting the doubled-revenue headline no longer carries the stock on its own.
That lowered bar cuts both ways. Strong growth is already assumed; what is not assumed is confidence in the full-year target. The central question is whether QT Imaging can show third-quarter revenue and a fourth-quarter pipeline large enough to make $39 million look achievable. If it can, the reaffirmation becomes a credibility win. If not, a guidance cut would confirm what the share price already seems to suspect.